Recapitulating monocyte extravasation to the synovium in an organotypic microfluidic model of the articular joint.


Journal

Biofabrication
ISSN: 1758-5090
Titre abrégé: Biofabrication
Pays: England
ID NLM: 101521964

Informations de publication

Date de publication:
07 07 2021
Historique:
received: 12 02 2021
accepted: 17 06 2021
pubmed: 18 6 2021
medline: 10 11 2021
entrez: 17 6 2021
Statut: epublish

Résumé

The synovium of osteoarthritis (OA) patients can be characterized by an abnormal accumulation of macrophages originating from extravasated monocytes. Since targeting monocyte extravasation may represent a promising therapeutic strategy, our aim was to develop an organotypic microfluidic model recapitulating this process. Synovium and cartilage were modeled by hydrogel-embedded OA synovial fibroblasts and articular chondrocytes separated by a synovial fluid channel. The synovium compartment included a perfusable endothelialized channel dedicated to monocyte injection. Monocyte extravasation in response to chemokines and OA synovial fluid was quantified. The efficacy of chemokine receptor antagonists, RS-504393 (CCR2 antagonist) and Cenicriviroc (CCR2/CCR5 antagonist) in inhibiting extravasation was tested pre-incubating monocytes with the antagonists before injection. After designing and fabricating the chip, culture conditions were optimized to achieve an organotypic model including synovial fibroblasts, articular chondrocytes, and a continuous endothelial monolayer expressing intercellular adhesion molecule-1 and vascular cell adhesion molecule-1. A significantly higher number of monocytes extravasated in response to the chemokine mix (

Identifiants

pubmed: 34139683
doi: 10.1088/1758-5090/ac0c5e
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Creative Commons Attribution license.

Auteurs

Carlotta Mondadori (C)

IRCCS Istituto Ortopedico Galeazzi, Cell and Tissue Engineering Laboratory, 20161 Milan, Italy.

Silvia Palombella (S)

IRCCS Istituto Ortopedico Galeazzi, Cell and Tissue Engineering Laboratory, 20161 Milan, Italy.

Shima Salehi (S)

IRCCS Istituto Ortopedico Galeazzi, Cell and Tissue Engineering Laboratory, 20161 Milan, Italy.

Giuseppe Talò (G)

IRCCS Istituto Ortopedico Galeazzi, Cell and Tissue Engineering Laboratory, 20161 Milan, Italy.

Roberta Visone (R)

Department of Electronics, Information and Bioengineering, Politecnico di Milano, 20133 Milan, Italy.

Marco Rasponi (M)

Department of Electronics, Information and Bioengineering, Politecnico di Milano, 20133 Milan, Italy.

Alberto Redaelli (A)

Department of Electronics, Information and Bioengineering, Politecnico di Milano, 20133 Milan, Italy.

Valerio Sansone (V)

IRCCS Istituto Ortopedico Galeazzi, 20161 Milan, Italy.

Matteo Moretti (M)

IRCCS Istituto Ortopedico Galeazzi, Cell and Tissue Engineering Laboratory, 20161 Milan, Italy.
Regenerative Medicine Technologies Lab, Ente Ospedaliero Cantonale, 6900 Lugano, Switzerland.
Euler Institute, Faculty of Biomedical Sciences, Università della Svizzera Italiana, 6900 Lugano, Switzerland.

Silvia Lopa (S)

IRCCS Istituto Ortopedico Galeazzi, Cell and Tissue Engineering Laboratory, 20161 Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH